Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.28

€4.28

0.940%
0.04
0.940%
-

-

 
20:04 / Tradegate WKN: A41FTP / Name: Innocan Pharma Corp. / Stock / ? /

Innocan Pharma Corp. Stock

The Innocan Pharma Corp. stock is trending slightly upwards today, with an increase of €0.040 (0.940%) compared to yesterday's price.

Pros and Cons of Innocan Pharma Corp. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs

Herzliya, Israel and Calgary, Alberta – February 09, 2026 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and

Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering

Herzliya, Israel and Calgary, AB – January 27, 2026 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company

Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering

Herzliya, Israel and Calgary, AB – 2 January 2026– Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing